Skip to content
20-F

Annual Report (Foreign)

SIMCERE PHARMACEUTICAL GROUP

0001104659-12-028253

← back to feed
Filed
Apr 25, 2012 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2011 · Dec 31, 2011 105.74M sh
Capex FY 2011 · Dec 31, 2011 ¥160.16M
Capex FY 2011 · Dec 31, 2010 ¥172.39M
Capex FY 2011 · Dec 31, 2009 ¥120.8M
Cash And Equivalents FY 2011 · Dec 31, 2011 ¥209.85M
Cash And Equivalents FY 2011 · Dec 31, 2010 ¥273.58M
Cash And Equivalents FY 2011 · Dec 31, 2009 ¥442.49M
Cash And Equivalents FY 2011 · Dec 31, 2008 ¥812.81M
Short Term Debt FY 2011 · Dec 31, 2010 ¥360M
Stockholders Equity FY 2011 · Dec 31, 2010 ¥1.88B
Current Liabilities FY 2011 · Dec 31, 2010 ¥1.01B
Total Liabilities FY 2011 · Dec 31, 2010 ¥1.12B
Current Assets FY 2011 · Dec 31, 2010 ¥1.39B
Total Assets FY 2011 · Dec 31, 2010 ¥3.22B
Stock Repurchased FY 2011 · Dec 31, 2009 ¥297.79M
Eps Diluted FY 2011 · Dec 31, 2009 ¥0.23
Eps Basic FY 2011 · Dec 31, 2009 ¥0.23
Sga Expense FY 2011 · Dec 31, 2009 ¥222.12M
Rd Expense FY 2011 · Dec 31, 2009 ¥132.98M
Net Income FY 2011 · Dec 31, 2009 ¥26.43M
Operating Income FY 2011 · Dec 31, 2009 ¥102.21M
Gross Profit FY 2011 · Dec 31, 2009 ¥1.54B
Cost Of Revenue FY 2011 · Dec 31, 2009 ¥320.95M